My prediction.......Cordis is sent to the bench and JNJ brings in a designated hitter to take this DES to the market. Rumor is Cordis is having mgmt. problems, JNJ is courting a stent pro, and Cordis laying off alot of people. Sounds like they have a few problems aside from Cypher.
DealMaker is the source of more misinformation than virtually anyone I have read on this board. In talking to the interventional cardiology community, I can tell you that there are probably 50,000 patients in the wings waiting for approval of the CYPHER to come in and have their coronary disease treated. Many patients are refusing bare stents currently. W/R to approval, it will be in mid March (end of story). Cordis has probably added 100 new positions in the last year (layoffs; I don't think so). JNJ is one of the most solid companies ever ( a $38 billion/year company with18 consective years with double digit growth!) This stock is a steal at $50. Shorts should take their losses and go home.
You've got an incredible imagination. Do you just dream this stuff up or is it drug induced?
Cardiologists can't wait for DES to come out. All have reviewed the data and most believe it would be malpractice to not use DES. Cost will not be an issue as cardiologists will use subsequent PTCAs spaced 30 days apart to maximize reimbursement. With the excellent clinical data generated by Cypher, Cordis could sell this stent without a sales force by just taking orders.